TickerGuard
Buy Day today: Neutral (54) Mixed market breadth · no major macro event
VXRT

Vaxart Inc

Healthcare · Biotechnology

0.449$ -1.1% vs. previous close Closing price · As of: Sep 29, 2026

Statements

Income Statement

Vaxart Inc (VXRT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Revenue" came in at 237 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement VXRT
Line item 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
240 229 243 234 229 235 196 177 142 108 90 – – 10 35 15 34 34 69 25 9.3 5.8 4.2 9.9 4.0 0.9 0.1 7.4 29 237
174 174 167 155 153 153 120 81 88 67 63 – – 2.0 4.0 1.5 20 20 51 3.6 0.1 12 17 15 20 49 3.3 4.5 4.4 –
66 55 76 78 76 82 76 95 54 41 27 – – 8.5 31 13 13 14 18 21 9.2 -6.5 -13 9.9 -16 -48 0.1 2.9 29 237
17 19 22 16 14 15 21 29 60 58 29 19 13 16 26 18 15 16 18 20 26 12 17 15 20 49 81 68 74 202
47 32 44 47 48 53 51 62 28 69 33 26 12 10.0 6.2 5.4 14 14 6.9 6.6 5.6 2.6 6.7 6.2 15 22 29 23 21 18
55 61 78 73 72 -35 60 90 106 123 61 45 25 26 32 23 33 34 28 29 34 0.1 24 26 14 25 115 86 95 219
11 -5.7 -1.4 5.8 3.6 117 3.7 -13 -52 -123 -61 -45 -25 -18 -1.2 -9.8 -20 -22 -12 -20 -25 -9.1 -22 -16 -30 -73 -115 -83 -66 18
4.0 0.0 5.7 0.0 3.6 2.1 2.1 1.4 2.2 3.1 3.7 3.5 3.9 1.1 0.2 0.2 0.0 1.3 0.2 0.0 0.3 1.8 2.7 2.4 1.9 1.5 1.3 1.4 3.0 2.8
8.0 -16 -16 7.6 4.1 116 2.7 -13 -51 -121 -61 -39 -26 -19 -0.9 -9.5 -8.6 -8.8 -11 -19 -25 -9.6 -18 -18 -32 -70 -108 -82 -67 17
-6.2 -4.7 20 2.5 0.1 11 0.6 -6.6 4.7 -2.9 -0.8 -14 -2.8 1.1 -1.8 -2.0 0.1 0.1 -0.3 -0.1 0.4 0.3 0.1 0.5 0.2 0.1 0.1 0.3 0.3 0.5
13 -11 -22 3.3 4.4 105 2.1 -6.8 -50 -128 -59 47 -19 -19 0.9 -4.5 -8.7 -8.9 -11 -19 -25 -12 -18 -19 -32 -70 -108 -82 -67 16
19 4.2 10 16 13 127 26 20 -34 -107 -54 -34 -21 -17 -0.3 -7.5 -17 -17 -8.9 -18 -25 -8.7 -12 -12 -28 -66 -101 -72 -55 28

Data as of: September 29, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?